Common questions about Mezavant (FAQ)
Q: Is Mezavant used to treat Crohn's disease or only ulcerative colitis?
A: Mezavant is officially indicated for the treatment of ulcerative colitis. Studies have explored the medicine's role in Crohn's disease, but official documentation indicates that the findings from these research trials were mixed or limited.
Q: How long does it typically take to see improvement in symptoms after starting Mezavant?
A: Official documents describing the induction phase indicate that the use of the highest daily dose is typically evaluated after eight weeks. Clinical trials on mesalazine generally assessed initial improvement in symptoms over intervals such as six to eight weeks.
Q: Are there any food or dietary restrictions associated with Mezavant?
A: Official documentation specifies that the tablets should be taken with food to support the proper delivery of the medicine. While there are no formal restrictions on specific types of food, adequate fluid intake is generally advised during treatment, which is linked to supporting kidney function.
Q: Is Mezavant considered safe to use during pregnancy?
A: Mezavant is designated for conditional use during pregnancy, meaning it should only be used if the potential benefit to the mother is considered to outweigh the potential risk. Official information indicates that the active ingredient, mesalazine, is described as crossing the placenta.
Q: Is Mezavant safe to use while breastfeeding?
A: Regulatory documents describe the medicine as being for conditional use while breastfeeding. Regulatory documents indicate that the active ingredient is excreted into breast milk in small amounts. There have been reports of diarrhea in breastfed infants whose mothers were taking mesalazine.
Q: Can a person who is allergic to sulfasalazine still take Mezavant?
A: A history of sulfasalazine allergy is listed as a caution or restriction in regulatory documents. This is because mesalazine is chemically related to sulfasalazine, and there is a possibility of developing a cross-hypersensitivity reaction.
Q: Why is it important to continue taking Mezavant even when symptoms improve?
A: Mezavant is formally indicated for the maintenance of remission in ulcerative colitis. The continued use of the medicine, even when symptoms have improved, is intended to support the prevention of recurrence or flaring of the chronic condition.
Q: What are the signs of an allergic reaction to Mezavant that require immediate attention?
A: Official documents list signs that have been associated with serious hypersensitivity reactions. These signs include unexplained bleeding, bruising, or severe skin rashes, chest pain or rapid heartbeat, and swelling of the face, lips, or throat.
Q: Do patients with pre-existing skin conditions need extra caution when using Mezavant?
A: Official documentation states that caution or medical advice is necessary for patients who have pre-existing skin issues, such as atopic dermatitis or atopic eczema. This caution is noted due to a reported potential for certain skin-related side effects to worsen.
Q: How does Mezavant differ from other mesalazine brands like Pentasa or Asacol?
A: The main difference lies in the delivery system. Mezavant utilizes MMX technology, which is specifically designed to release the mesalazine across the entire colon (large intestine). Other mesalazine products are formulated to release the active ingredient in different areas, such as the entire length of the gut, including the small intestine.
Q: Is Mezavant a type of steroid or immunosuppressant?
A: Mezavant is classified as an aminosalicylate, functioning as an anti-inflammatory agent. The official pharmacological class indicates that it is not classified as a corticosteroid (steroid) or a systemic immunosuppressant.
Q: Does Mezavant require a prescription?
A: Yes, Mezavant is a specialized medication that is only available with a doctor's prescription.
Q: Is it normal to see a tablet shell or casing in the stool when taking Mezavant?
A: Yes, the prolonged-release tablet uses an inert outer shell or matrix to ensure the controlled release of the medicine. It is common for this empty tablet shell (sometimes called a 'ghost pill') to pass into the stool after the active medicine has been absorbed.
Q: Is it necessary to avoid alcohol while taking Mezavant?
A: Regulatory guidance does not formally mandate the avoidance of alcohol. However, some studies have shown that alcohol could potentially affect the release characteristics of the mesalazine formulation. Some patients may be advised to limit intake, as alcohol may also irritate the gut.
Q: Does Mezavant affect blood sugar levels or diabetes management?
A: While not a common side effect, official documents mention that low blood sugar (hypoglycaemia) may be a symptom of taking an overdose of mesalazine. No routine effect on diabetes management is stated in the core warnings for standard use.
Q: Does Mezavant make a person more sensitive to the sun or cause photosensitivity?
A: Sensitivity to sunlight (photosensitivity reaction) is documented as a less common side effect associated with mesalazine products. Due to this possibility, patients are typically advised to take precautions when exposed to direct sunlight.
Q: Can Mezavant affect a person's ability to drive or operate machinery?
A: Regulatory documents state that Mezavant is generally considered unlikely to have any effect on the ability to drive or use machines. However, patients are typically advised not to drive or operate machinery until they have determined how the medicine affects them personally.
Q: Does Mezavant affect fertility in men or women?
A: Official information suggests there is generally no evidence that mesalazine will reduce fertility in either men or women. However, rare case reports of reversible male infertility associated with mesalazine treatment have been noted in medical literature.
Q: Can Mezavant affect sleep or cause insomnia?
A: Official documentation lists feeling sleepy or tired (somnolence) as an uncommon side effect. Insomnia itself is not explicitly listed in common or uncommon side effect categories.
Q: Can Mezavant cause hair loss?
A: Hair loss (alopecia) is documented as a less common side effect associated with mesalazine products.
Q: Can Mezavant cause problems with the pancreas (pancreatitis)?
A: Yes, an inflamed pancreas (pancreatitis) is listed as an uncommon side effect in regulatory documents. This condition is often associated with pain in the upper abdomen and back.
Q: Does Mezavant interfere with any standard laboratory test results?
A: Regulatory documents report possible interference with measurements of a hormone metabolite called urinary normetanephrine when tested by liquid chromatography. This interference could potentially lead to a false-positive test result.
Q: Is Mezavant only available in a tablet form?
A: The Mezavant brand itself is formulated as a prolonged-release tablet. However, the active ingredient mesalazine is available from other manufacturers in different forms, including suppositories, enemas, and granules.
Q: Can taking Mezavant affect my blood pressure?
A: Yes, changes in blood pressure are listed as a common side effect associated with Mezavant in official documentation.
Q: Is it normal for my urine to change color when taking Mezavant?
A: Yes, the active ingredient, mesalazine, may produce a red-brown urine discoloration if it comes into contact with sodium hypochlorite bleach (often found in toilet water). This chemical reaction is described in regulatory documents as being harmless.
Q: Why is my doctor prescribing Mezavant instead of a different mesalazine product?
A: The different mesalazine products are formulated to work in specific locations within the digestive system. Mezavant's MMX technology is specifically designed to ensure the medicine is released gradually across the entire colon.
Q: Can patients cut the Mezavant tablet in half to adjust the dose?
A: No. Regulatory documents specify that the tablets should be swallowed whole and must not be crushed, broken, or chewed. This requirement is necessary to maintain the integrity of the specialized prolonged-release mechanism.
